Annual Scientific SessionsThis 4-day comprehensive learning experience features a wide variety of scientificsessions, symp...
Best professionalorganization toget healthproviders the mostup-to-date guide-lines, as we enterthe new era ofATP IV!See ww...
I find theconference tobe academicallychallenging.It stimulatesa continuedinterest toprovide the bestcare I can formy pati...
Target AudienceThis activity is designed to meet the needs of physicians, physician assistants, pharmacists,registered nur...
(register on page 9 or online) Wednesday, May 29, 2013–Thursday, May 30, 2013OverviewThis 1.5 day class will review the la...
OverviewThis intensive 2-day training course offers an in-depth reviewof the core curriculum in Clinical Lipidology for he...
Jane Armitage, FRCP, FFPHProfessor of Clinical Trials and Epidemiology and HonoraryConsultant in Public Health MedicineCli...
Call For AbstractsThe 2013 NLA Annual Scientific SessionsCommittee invites the submission of abstracts tobe presented at t...
Red Rock Resort11011 West Charleston BoulevardLas Vegas, Nevada 89135866.767.7773For reservations, call 1.866.767.7773 and...
PRE-CONFERENCECOURSE ACCREDITATIONLipid Academy™ Course– AccreditationCME credit provided by the National Lipid Associatio...
Registration:RegistrationandpaymentmustbereceivednolaterthanMay3,2013.Afterthisdateasyllabusandnamebadgecannotbeguaranteed...
6816SouthpointParkway,Suite1000Jacksonville,FL32216ScanthiscodewithyoursmartphoneortabletformoreinformationScan this code ...
Upcoming SlideShare
Loading in...5
×

NLA Scientific Sessions 2013

323

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
323
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

NLA Scientific Sessions 2013

  1. 1. Annual Scientific SessionsThis 4-day comprehensive learning experience features a wide variety of scientificsessions, symposia, case presentations and poster sessions that providepractical solutions for applying the latest research in your clinical practice.Allsessions and educational events are evidence-based and clinically relevant to thepracticing lipidologist.Town HallThe Annual Scientific Sessions include an opening Town Hall session on the Roleof PCSK9 Inhibition on Intensive Lipid Lowering.Exhibit Hall, Workshops and Non-CME EventsSee the latest pharmaceuticals, equipment and other essential products andservices to help you practice more effectively in the Exhibit Hall, at sponsoredworkshops, and at special interest non-CME sessions.Lipid Academy™The NLA’s Lipid Academy™ provides a comprehensive, in-depth indoctrination tolipid science and is open to all health care professionals interested in developinga core competency in the diagnosis and treatment of dyslipidemia.The LipidAcademy™ course provides health care professionals with the knowledge andtools necessary to work effectively in a lipid practice, and serves as a preparatorycourse for other advanced lipid training.Masters in Lipidology™The NLA’s Masters in Lipidology™ offers an in-depth review of the core curriculumin Clinical Lipidology for health care professionals who desire to practice at anadvanced level.The case-based, interactive agenda will improve your clinicaldecision-making skills and help prepare you for certification. Learn from leadingexperts, assess your knowledge of lipid science and advance your personalstandard of practice.The Translation of HDL Science Master ClassThe Translation of HDL Science Master Class is a 1½-day live, intensive trainingcourse that presents the latest data on HDL metabolism, nomenclature,functionality, and subfractions, as well as a comprehensive overview of currentresearch on therapies that affect HDL metabolism. Improve your knowledge andcompetence on these topics to make informed decisions about lipid therapiesand reduce the risk of cardiovascular disease in your patients.Things to See in Las VegasLas Vegas has the well-deserved title as the entertainment capital of the world.Shows, world-class cuisine, golf courses around every corner, history and nature—24 hours a day is hardly enough. Hands down, Elvis said it best: “Viva Las Vegas!”MEETING HIGHLIGHTSNational Lipid Association 2013 AnnualScientific Sessions in Las VegasIt is our pleasure to invite you to the National Lipid Association’s 2013 AnnualScientific Sessions in Las Vegas, Nevada.The National Lipid Association (NLA) is ayoung and dynamic organization devoted to serving a fast-growing community ofhealth care professionals who share a common goal—to enhance the practiceof lipid management in clinical medicine and to reduce the morbidity andmortality associated with atherosclerotic disease. The NLA gives you exclusiveaccess to unmatched experiences,leadership opportunities andeducational offerings designed to meet your needs and providesupport as you advance your career.National Lipid Association2013 Annual ScientificSessions in Las VegasAccess to world renownedthought leadersPre-Conference Workshops–From Basic Lipidology toVascular BiologyNew Lipid GuidelinesPerspectives–Neil Stone, MDOver 30+ hours of CME andCE credit for physicians,registered nurses, pharmacistsand registered dietitiansNLA Special Town Hall Session:Role of PCSK9 Inhibition onIntensive Lipid Lowering—Chair,Peter P.Toth, MD, PhD, FNLALive Discussion ofComplex CasesPrepare for Certification inClinical LipidologyKEYNOTE PRESENTATIONFriday, May 31, 2013Sterol-Regulatory-Element-Binding-Proteins: MasterRegulators of Lipid andLipoprotein Metabolism9:00–10:00 AMMarshall B. Elam, MD, PhDProfessor, Pharmacologyand Medicine(Cardiovascular Disease)University of TennesseeHealth Sciences CenterStaff Cardiologist and DirectorLipid Metabolism ClinicsVeterans Affairs Medical CenterMemphis,TNThis activity is sponsored by the National Lipid Association. This activity is Co-provided/Co-sponsoredby Postgraduate Institute for Medicine.
  2. 2. Best professionalorganization toget healthproviders the mostup-to-date guide-lines, as we enterthe new era ofATP IV!See www.lipid.org/sessionsfor workshop descriptions.Agenda and faculty subjectto change. Checkwww.lipid.org/sessionsfor updates.Register atwww.lipid.org/sessions”“SCIENTIFIC SESSIONSWednesday, May 29, 20137:30−8:00 AM Masters in LipidologyTMRegistration8:00 AM−5:30 PM Masters in LipidologyTM9:30−10:00 AM Lipid AcademyTMRegistration10:00 AM−5:45 PM Lipid AcademyTM9:30−10:00 AM HDL Masters Registration10:00 AM−5:30 PM The Translation of HDL Science Master Class5:00−6:00 PM Fellows and Trainees ReceptionThursday, May 30, 20137:00 AM−3:55 PM Masters in LipidologyTM7:30 AM−Noon Lipid AcademyTM8:00 AM−12:30 PM The Translation of HDL Science Master Class4:00−6:00 PM NLA 2013 OPENING SESSIONS4:00−4:15 PM Welcome and Introductions4:15−5:45 PM NLA Town Hall: Role of PCSK9 Inhibition on Intensive Lipid Lowering6:00–7:00 PM WELCOME RECEPTION7:00−9:00 PM Satellite SymposiaFriday, May 31, 20136:00−8:00 AM Satellite Symposia8:00−9:00 AM CONTINENTAL BREAKFASTKEYNOTE LECTURE9:00−10:00 AM Keynote Presentation: Sterol-Regulatory-Element-Binding— Marshall B. Elam, MD, PhDProteins: Master Regulators of Lipid and Lipoprotein Metabolism10:00−10:30 AM BREAK IN EXHIBIT HALLSESSION I: FOCUS ON METABOLIC SYNDROME10:30−10:50 AM Adiposity and Dyslipidemia Consensus Document Harold E. Bays, MD, FNLA*10:50−11:10 AM Sleep Apnea, Insulin Resistance, and Dyslipidemia Virend K. Somers, MD, PhD11:10−11:30 AM Molecular and Cellular Effects of Inflammation on Ishwarlal Jialal,MD,PhD,FNLA*Insulin Resistance11:30−11:50 AM Overview of Obesity Drugs: Mechanism and Clinical Efficacy George Bray, MD11:50 AM−12:00 PM Panel Sessions Q and A12:00−1:00 PM Young Investigator Award (ORAL POSTER PRESENTATIONS)1:00−2:00 PM LUNCH AND POSTER SESSIONSSPECIAL SESSION2:00−2:30 PM New Lipid Guidelines Perspectives Neil J. Stone MD, FNLA*SPECIAL SESSION2:30−3:00 PM Vulnerable Blood Paul A. Gurbel, MDSESSION II: FISH OIL SYMPOSIUM3:00−3:20 PM Fish Oils and Insulin Sensitivity/Resistance Naima Moustaïd-Moussa, PhD3:20−3:40 PM DHA and The Brain: Is it an Essential Nutrient? Susan E. Carlson, PhD3:40−4:00 PM Anti-inflammatory Effects of Fish Oils Oswald Quehenberger, PhD4:00−4:10 PM Panel Sessions Q and ASESSION III: HDL TRANSLATIONAL SCIENCE4:10−4:30 PM HPS-2 THRIVE Jane M.Armitage, FRCP, FFPH4:30−4:50 PM HDL Particles and CHD Risk Rachel H. Mackey, PhD, MPH4:50−5:10 PM Transcriptional Regulation of the ApoA-1 Promoter Norman C.W.Wong, MD, FRCP(C)5:10−5:30 PM NLA HDL Consensus Statement Peter P.Toth, MD, PhD, FNLA*5:30−5:45 PM Panel Sessions Q and A7:00−9:00 PM Satellite Symposia*Denotes Diplomate,American Board of Clinical Lipidology (ABCL)
  3. 3. I find theconference tobe academicallychallenging.It stimulatesa continuedinterest toprovide the bestcare I can formy patients.See www.lipid.org/sessionsfor workshop descriptions.Agenda and faculty subjectto change. Checkwww.lipid.org/sessionsfor updates.Register atwww.lipid.org/sessions“”Saturday, June 1, 20136:00−8:00 AM Satellite Symposia8:00−9:00 AM CONTINENTAL BREAKFAST8:45−9:00 AM MWLA/SWLA BUSINESS MEETINGSession IV: Statin Safety Update: A Focus on the Mechanisms9:00−9:20 AM USAGE Study Subgroup Analysis Matthew K.Ito,PharmD,CLS,FNLA9:20−9:40 AM Genetic Risk Underlying Statin-Induced Myopathy Georgirene D.Vladutiu, PhD9:40−10:00 AM Statins and Risk for Diabetes Mellitus Paul M. Ridker, MD, MPH10:00−10:20 AM Statins and Cognitive Impairment Larry B. Goldstein, MD10:20−10:30 AM Panel Sessions Q and A10:30–11:00 AM BREAK IN EXHIBIT HALLSession V: Pediatric Session—What Age to Initiate Pharmacotherapy?11:00−11:20 AM Cascade Screening for FH Paul N. Hopkins, MD, MSPH*11:20−11:40 AM Pediatric Dyslipidemia Guidelines Donnie P.Wilson, MD, FNLA*11:40 AM−12:00 PM Management of Adolescent Metabolic Syndrome Catherine J. McNeal, MD, PhD, FNLA*and Dyslipidemia12:00−12:10 PM Panel Sessions Q and A12:10−12:30 PM NLA and Foundation News and Notes/PLA Business Meeting12:30−1:30 PM LUNCH AND POSTER SESSION VIEWINGSession VI: General Session—Vascular Biology and Advanced Lipoprotein Metabolism1:30−1:50 PM Lipoprotein Effects of Incretin Hormones: Implications Sanjay Rajagopalan, MDfor Clinical Practice1:50−2:10 PM Roles of Micro RNAs in the Regulation of Lipid Metabolism Kasey C.Vickers, PhD2:10−2:30 PM Statins and Blood Pressure Maciej Banach, MD, FNLA2:30−2:50 PM Novel Insights into the Production and Atherogenicity Marlys L. Koschinsky, PhDof Lipoprotein(a)2:50−3:10 PM Biomechanical Stress and Its Association With Atherosclerosis Patrick M. Moriarty, MD, FNLA3:10−3:20 PM Panel Sessions Q and ASession VII: Assessing CVD Risk3:20−3:40 PM Genetic Risk for Myocardial Infarction Sekar Kathiresan, MD3:40−4:00 PM Lifetime Risk Donald M. Lloyd-Jones, MD, ScM4:00−4:20 PM 10-Year Risk Ralph B. DAgostino, Sr. PhD4:20−4:30 PM Panel Sessions Q and ASession VIII: Debate4:30−5:05 PM CIMT as Risk Marker Joseph F. Polak, MD, MPHVs.Allen J.Taylor MD5:05−5:15 PM Panel Sessions Q and A5:15−5:30 PM NELA/SELA Business Meeting6:00−7:00 PM HONORS AND AWARDS CEREMONYFoundation of the National Lipid Association7:00−10:00 PM DANCING IN THE DESERTSunday, June 2, 20138:00−9:00 AM CONTINENTAL BREAKFASTSession IX: Clinical Applications9:00−9:45 AM Statistics for Lipidologists: Concepts Controversies Robert A.Wild, MD, PhD, MPH, FNLA*Kevin C. Maki, PhD, FNLA, CLS9:45−10:00 AM Panel Sessions Q and A10:00−10:25 AM Motivational Interviewing to Improve Patient Compliance Eileen S. Myers, MPH, RD, LDN10:25− 10:50 AM Cooking for Dyslipidemia Mary N. Felando, MS, RD, CLS, FNLA10:50−11:00 AM Panel Sessions Q and A*Denotes Diplomate,American Board of Clinical Lipidology (ABCL)
  4. 4. Target AudienceThis activity is designed to meet the needs of physicians, physician assistants, pharmacists,registered nurses, nurse practitioners and registered dietitians with an interest in lipidmanagement.Type of ActivityLive Activity; Application (Sessions I, IV-V, IX), Knowledge (Keynote lecture, Special SessionsNew Lipid Guidelines Perspectives & Vulnerable Blood, Sessions II-III,VI-VIII)Educational ObjectivesAt the conclusion of this activity, all participants should be able to:Keynote Lecture: Sterol-Regulatory-Element-Binding-ProteinsⅢ Describe cellular and molecular mechanisms that mediate hyperlipidemia inhyperinsulinemic states including obesity and type II diabetes mellitusSession I: Focus on Metabolic SyndromeⅢ Apply various therapies to treat patients with metabolic dysfunction and reduce theirindividual risk factors in the context of primary preventionⅢ Develop a systematic management plan to reduce risk factors in patients with insulinresistance, abdominal obesity, and other metabolic syndrome criteriaⅢ Identify novel therapies for the treatment of insulin resistance, visceral adiposity and obesitySpecial Session: New Lipid Guidelines PerspectivesⅢ Define treatment goals for patients with dyslipidemia based on the current guidelines forlipid management issued by the National Cholesterol Education Program Adult Treatment PanelSpecial Session: Vulnerable BloodⅢ Review the clinical utility of genotyping and platelet function testing in patients treated withantithrombotic agentsSession II: Fish Oil SymposiumⅢ Review the use of Omega-3 Fatty Acids in the management of lipoprotein disordersⅢ Interpret evidence from recent clinical trials of Omega-3 Fatty Acids and those in clinicaldevelopmentSession III: HDL Translational ScienceⅢ Discuss recent evidence regarding the utility of HDL as a target for CVD risk modification andthe clinical implications for patient managementⅢ Describe the efficacy, safety, and mechanisms of action of novel HDL-targetingpharmacotherapiesSession IV: Statin Safety Update: A Focus on the MechanismsⅢ Develop insight and skills in assessing and managing adverse events associated with lipid-altering drugsⅢ Identify contributing factors and implications of nonadherence to lipid lowering therapies inlight of recent findingsSession V: Pediatric Session: What Age to Initiate Pharmacotherapy?Ⅲ Illustrate the importance of universal screening during childhood and cascade lipidscreening of family members of known FH patientsⅢ Implement appropriate diagnosis strategies in pediatric patientsSession VI: General Session: Vascular Biology and AdvancedLipoprotein MetabolismⅢ Discuss the various pathways of atherogenesis, especially the role of apolipoproteins ascarriers of cholesterol, and the role of inflammationⅢ Explain the mechanisms of action and expected clinical effects of incretin-based therapiesⅢ Evaluate the role of Micro RNAs in the regulation of lipid metabolismSession VII: Assessing CVD RiskⅢ Compare and contrast the effectiveness of available risk assessment guidelines inpredicting10-year and lifetime CV riskSession VIII: Debate–CIMT as Risk MarkerⅢ Identify the potential contribution of carotid IMT to cardiovascular risk assessmentSession IX: Clinical ApplicationsⅢ Discuss epidemiologic and statistical evidence related to cardiovascular disease riskⅢ Apply more effective physician/patient communication techniques to support patients’efforts at self-management and compliance to therapiesⅢ Assess the impact of diet, weight reduction, exercise and behavior modifications oncardiovascular risk and risk factorsFor Registered Nurses and Nurse Practitioners OnlyⅢ Provide appropriate care and counsel for patients and their familiesNLA ANNUAL SCIENTIFIC SESSIONSFriday, May 31 • 9:00 AM–5:45 PM Saturday, June 1 • 9:00 AM–5:15 PMSunday, June 2 • 9:00–11:00 AM$595 NLA Members, $1000 Non-members, $75 TraineesNLA LIPID ACADEMY™Wednesday, May 29 –10:00 AM–5:45 PMThursday, May 30 –7:30 AM–NOON$495 NLA Members • $900 Non-Members • $0 TraineesOverviewThe NLA’s Lipid Academy™ provides a comprehensive, in-depth indoctrination to lipid science and is open to allhealth care professionals interested in developing a corecompetency in the diagnosis and treatment of dyslipidemia.The interactive Lipid Academy™ course provides healthprofessionals with the knowledge and tools necessary towork effectively in a lipid practice, and will serve as apreparatory course for the Annual Scientific Forum and otheradvanced lipid training.The Lipid Academy™ is offered as a 1.5-day course prior toeach scientific meeting conducted by the NLA.Target AudienceThis activity is designed to meet the needs of physicians,physician assistants, pharmacists, registered nurses, nursepractitioners and registered dietitians with an interest in lipidmanagement.Type of ActivityKnowledgeLearning ObjectivesAt the conclusion of this activity, participants should be ableto:Ⅲ Assess the impact of diet, exercise and behaviormodifications on cardiovascular risk and risk factorsⅢ Critically appraise landmark clinical trials and applyimportant research to daily clinical practiceⅢ Describe aggressive therapies for the management of complexlipid disorders,metabolic syndrome and residual riskⅢ Describe cardiometabolic risk factors and their impact oncardiovascular healthⅢ Evaluate current and novel advanced lipid tests andbiomarkers for atherosclerosis and their potentialapplications for CV risk detection and management, aswell their limitationsⅢ Identify primary and secondary causes of dyslipidemiaⅢ Identify the functions and sources of cholesterol andtriglycerides, and describe the role of lipoproteins inatherosclerosisⅢ Outline current guidelines on the diagnosis, managementand treatment of patients with dyslipidemiaⅢ Outline the principles of pharmacological management ofdyslipidemia, including the effect of each agent onatherosclerotic disease, serum lipids, and lipoproteinmetabolismFor Registered Nurses and Nurse Practitioners OnlyⅢ Provide appropriate care and counsel for patients andtheir familiesPRE-CONFERENCECOURSESPROGRAM OBJECTIVES
  5. 5. (register on page 9 or online) Wednesday, May 29, 2013–Thursday, May 30, 2013OverviewThis 1.5 day class will review the latest evidence andresearch on HDL metabolism and functionality, targets oftherapy, and existing and novel HDL raising therapies.Participants will be expected to improve their HDL knowledgeand competence, expand the depth of their understandingof lipid science, and help their patients make informeddecisions about lipid therapies to reduce the risk ofcardiovascular disease.Target AudienceTThis activity is designed to meet the needs of physicians,pharmacists, registered nurses, registered dietitians andother allied health care professionals and specialists withadvanced knowledge and interest in lipid management.Learning ObjectivesUpon completion of the educational activity, participantsshould be able to:Ⅲ Evaluate the role of HDL-C as a marker of risk forcardiovascular disease based on epidemiologic cohortsfrom around the worldⅢ Review impact of specific genetic polymorphisms onserum HDL-C and risk for CHDⅢ Outline the various HDL receptors and metabolicpathways and their pleiotropic effectsⅢ Identify the genetic causes of low and high serum HDL-Cas well as the clinical and research implications of thesegenetic disordersⅢ Review the role of HDL subfractions and apolipoproteinsas risk factorsⅢ Describe the function of the HDL proteome and lipidomein coronary artery diseaseⅢ Outline the clinical benefits for implementing therapeuticlifestyle and dietary changes to elevate HDL and reduceTriglyceridesⅢ Compare and contrast the relative effectiveness of existingtreatments to raise HDL and reduce CVD risk, based onthe current clinical trial evidenceⅢ Identify novel HDL therapies in development and assesstheir role in raising HDL-C and reversing atherosclerosisⅢ Review the strengths and weaknesses of emerging HDL-based therapeuticsFor Registered Nurses and Nurse Practitioners OnlyⅢ Provide appropriate care and counsel for patients andtheir familiesCore FacultyBenjamin J. Ansell, MD, FNLA*Co-DirectorUCLA Cholesterol Hypertension & AtherosclerosisManagement ProgramProfessor of MedicineDivision of CardiologyUCLA School of MedicineLos Angeles, CAH. Bryan Brewer, Jr., MD, FNLA*DirectorWashington Cardiovascular AssociatesSenior Research ConsultantMedStar Research InstituteWashington, DCM. John Chapman, BSc, PhD, DScPresident, European Atherosclerosis SocietyDirectorINSERM (Dyslipidemia and Atherosclerosis Research)Paris, FranceMichael H. Davidson, MD, FNLA*Clinical ProfessorDirector of Preventive CardiologyThe University of Chicago Pritzker School of MedicineChicago, ILRobert S. Rosenson, MD, FNLA*Professor of MedicineMount Sinai School of MedicineDirectorCardiometabolic DisordersMount Sinai HeartNew York, NYPeter P. Toth, MD, PhD, FNLA*Director of Preventative CardiologyCGH Medical CenterSterling, ILProfessor of Clinical Family and Community MedicineUniversity of Illinois College of MedicinePeoria, ILProfessor of Clinical MedicineMichigan State University College of Osteopathic MedicineEast Lansing, MI*Denotes Diplomate,American Board of Clinical Lipidology(ABCL)PRE-CONFERENCECOURSESTRANSLATION OF HDL SCIENCE MASTER CLASSWednesday, May 29 –10:00 AM–5:30 PMThursday, May 30 –8:00 AM–12:30 PM$225 NLA Members • $495 Non-Members • N/A TraineesFacultyDean A. Bramlet, MD, FACC, FACP, FAHA, FNLA*Assistant Consulting Professor of MedicineDuke UniversityMedical DirectorHeart and Lipid Institute of FloridaSt. Petersburg, FLJoyce L. Ross, MSN, ANP, CLS, CRNP, FPCNA, FNLAClinical ConsultantPrivate PracticeUniversity of PennsylvaniaPhiladelphia, PAJoseph J. Saseen, PharmD, FASHP, FCCP, FNLA, BCPS, CLSProfessorClinical Pharmacy and Family MedicineUniversity of Colorado DenverAnschutz Medical CampusAurora, COJames A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA*Clinical Assistant Professor of MedicineNYU Medical SchoolNYU Center for Cardiovascular Disease PreventionDirectorBellevue Hospital Lipid ClinicNew York, NY*Denotes Diplomate,American Board of Clinical Lipidology(ABCL)NLA LIPID ACADEMY™ CONTINUEDWednesday, May 29, 2013–Session I9:30–10:00 AM Registration10:00–11:45 AM Atherosclerosis, Lipids and Lipoproteins James A. Underberg, MD, MS,FNLA*11:45 AM–12:15 PM Lunch12:15–1:50 PM Diagnosis, Clinical Appraisal and James A. Underberg, MD, MS,Treatment Guidelines FNLA*1:50–2:00 PM Break2:00–3:30 PM Clinical Trials Overview Joseph J. Saseen, PharmD,FNLA, CLS3:30–3:45 PM Break3:45–5:30 PM Treatment Targets and Pharmacologic Joseph J. Saseen, PharmD,Therapies FNLA, CLS5:30–5:45 PM Q & AThursday, May 30, 2013–Session II7:30–8:00 AM Breakfast8:00–9:15 AM Nonpharmacologic Therapies: Joyce L. Ross, MSN, ANP, CLS,Diet, Exercise, and Behavior Modification FNLA9:15–9:30 AM Break9:30–11:00 AM The Identification and Management of Dean A. Bramlet, MD, FNLA*Cardiometabolic Risk11:00–11:50 AM Advanced Risk Assessment: The Role of Dean A. Bramlet, MD, FNLA*Biomarkers and Diagnostic Testing11:50 AM–12:00 PM Q & A and Wrap-Up
  6. 6. OverviewThis intensive 2-day training course offers an in-depth reviewof the core curriculum in Clinical Lipidology for health careprofessionals who desire to practice at an advanced levelwithin the field. Learn from leading experts, assess yourknowledge of lipid science and advance your personalstandard of practice.Target AudienceThis activity is designed to meet the needs of physicians,physician assistants, pharmacists, registered nurses, nursepractitioners and registered dietitians with an interest in lipidmanagement.Type of ActivityApplicationLearning ObjectivesAt the conclusion of this activity, participants should be ableto:Ⅲ Assess traditional and emerging markers foratherosclerotic cardiovascular diseaseⅢ Critique the role of drug therapies, nutrition, andtherapeutic lifestyle changes in the management ofdyslipidemiasⅢ Discuss lipoprotein metabolism and the role of thevascular system in the pathogenesis of atherosclerosisⅢ Explain the role genetic disorders play in lipoproteinmetabolismⅢ Manage cardiometabolic risk factors of the metabolicsyndromeⅢ Manage dyslipidemias according to patient profilesFor Registered Nurses and Nurse Practitioners OnlyⅢ Provide appropriate care and counsel for patients andtheir familiesFacultyHarold E. Bays, MD, FACE, FTOS, FNLA*Medical Director/PresidentLouisville Metabolic and Atherosclerotic Research CenterLouisville, KYAlan S. Brown, MD, FACC, FAHA, FNLA*Interventional Cardiologist, Midwest Heart SpecialistsDirector, Midwest Heart Disease Prevention CenterClinical Associate Professor, Loyola UniversityMaywood, ILAnne C. Goldberg, MD, FACP, FAHA, FNLA*Associate Professor of MedicineWashington University School of MedicineSt. Louis, MOTerry A. Jacobson, MD, FACP, FNLA*Professor of MedicineDirector, Office of Health Promotion and Disease PreventionEmory UniversityAtlanta, GAKevin C. Maki, PhD, FNLA, CLSChief Science OfficerBiofortis Clinical ResearchAddison, ILCatherine J. McNeal, MD, PhD, FNLA*Associate Professor of Pediatrics and Internal MedicineTexas A&M Health Science CenterScott & White HealthcareTemple,TXCarl E. Orringer, MD, FACC, FNLA*Harrington-McLaughlin Chair in Preventive CardiovascularMedicineAssociate Professor of MedicineCase Western Reserve University School of MedicineCleveland, OHPeter P. Toth, MD, PhD, FNLA*Director of Preventative CardiologyCGH Medical CenterSterling, ILProfessor of Clinical Family and Community MedicineUniversity of Illinois College of MedicinePeoria, ILProfessor of Clinical MedicineMichigan State University College of Osteopathic MedicineEast Lansing, MI*Denotes Diplomate,American Board of Clinical Lipidology(ABCL)Wednesday, May 29, 20137:30–8:00 AM Registration & Breakfast8:00–8:10 AM Introduction & ARS Pre-Test8:10–10:00 AM Lipoprotein Metabolism and Genetic Alan S. Brown, MD, FNLA*Disorders10:00–10:10 AM Break10:10 –11:40 AM Subclinical Atherosclerosis Testing,Advanced Carl E. Orringer, MD, FNLA*Lipoprotein Testing and Inflammatory Markersfor CHD Risk Assessment and Management11:40–11:50 AM Break11:50 AM–12:35 PM Pediatric Dyslipidemia Catherine J. McNeal, MD,PhD, FNLA*12:35–1:05 PM Lunch1:05–2:50 PM Management of Metabolic Syndrome Harold E. Bays, MD, FNLA*and Diabetic Dyslipidemia2:50–3:00 PM Break3:00–4:40 PM Pharmacology and Pharmacologic Therapies Harold E. Bays, MD, FNLA*—Part I4:40–5:30 PM Case Presentations – Risk Assessment Carl E. Orringer, MD, FNLA*and TLC oriented casesPRE-CONFERENCECOURSESMASTERS IN LIPIDOLOGY™ COURSEWednesday, May 29 –8:00 AM–5:30 PMThursday, May 30 –7:00 AM–3:55 PM$695 NLA Members • $1,200 Non-Members • $395 TraineesTRANSLATION OF HDL SCIENCE MASTER CLASS CONTINUEDWednesday, May 29, 20139:30–10:00 AM REGISTRATION10:00–10:30 AM Introductions and Pre-Test10:30–11:45 AM HDL Epidemiology and History of Development into a TherapeuticTarget11:45 AM–12:00 PM Question and Answer Session12:00–12:30 PM LUNCH12:30–1:45 PM HDL Metabolism and Genetic Deficiency Disorders1:45–2:00 PM Question and Answer Session2:00–2:15 PM BREAK2:15–3:30 PM Dissecting HDL: Subfractionation, Functionality, Lipidomics, andProteomics3:30–3:45 PM Question and Answer Session3:45–4:00 PM BREAK4:00–5:15 PM Lifestyle Changes and HDL5:15–5:30 PM Question and Answer SessionThursday, May 30, 20138:00–8:30 AM BREAKFAST8:30–9:45 AM Current Therapies to Elevate HDL – Update on Clinical Trials9:45–10:00 AM Question and Answer Session10:00–10:15 AM BREAK10:15–11:45 AM Novel Therapeutic Approaches to Elevate HDL-C and Modulate HDLFunctionality11:45 AM–12:00 PM Question and Answer Session12:00–12:30 PM Wrap Up and HDL Master Class Post-TestThursday, May 30, 20137:00–7:30 AM Breakfast7:30–9:15 AM CVD Epidemiology and Risk Assessment Kevin C. Maki, PhD, FNLA, CLS9:15–9:25 AM Break9:25–10:40 AM Therapeutic Lifestyle Changes: Nutrition Anne C. Goldberg, MD, FNLA*and Non-Pharmacologic Therapies10:40–11:20 AM Case Presentations—Pharma Therapies, Anne C. Goldberg, MD, FNLA*Special Populations, Complex Cases11:20 AM–12:00 PM Lunch12:00–1:40 PM Pharmacology and Pharmacologic Terry A. Jacobson, MD, FNLA*Therapies—Part II1:40–1:50 PM Break1:50–3:40 PM Vascular Biology and Atherogenesis Peter P. Toth, MD, PhD, FNLA*3:40–3:55 PM ARS Post-Test, Board Review & Wrap-up
  7. 7. Jane Armitage, FRCP, FFPHProfessor of Clinical Trials and Epidemiology and HonoraryConsultant in Public Health MedicineClinical Trial Service Unit and Epidemiological Studies UnitUniversity of OxfordOxford, EnglandMaciej Banach, MD, FAHA, FESC, FASA, FRSPH, FNLAPresident, Polish Lipid Association (PoLA)Head, Department of HypertensionMedical University of LodzLodz, PolandHarold E. Bays, MD, FACE, FTOS, FNLA*Medical Director/PresidentLouisville Metabolic and Atherosclerotic Research CenterLouisville, KYGeorge Bray, MDBoyd ProfessorChief, Division of Clinical Obesity and MetabolismProfessorPennington Biomedical Research CenterBaton Rouge, LASusan E. Carlson, PhDAJ Rise Professor of NutritionUniversity of Kansas Medical CenterKansas City, KSRalph B. DAgostino, Sr. PhDMathematics and Statistics DepartmentProfessor of Mathematics/Statistics, Biostatistics andEpidemiologyExecutive Director MA/PhD Program in BiostatisticsDirector, Statistics and Consulting UnitDirector, Framingham Study: Statistics and DataManagementStatistical Consultant, New England Journal of MedicineEditor, Statistics in MedicineEditor, Encyclopedia of Clinical TrialsBoston UniversityBoston, MAMarshall B. Elam, MD, PhDProfessor, Pharmacology and Medicine(Cardiovascular Disease)University of Tennessee Health Sciences CenterStaff Cardiologist and Director, Lipid Metabolism ClinicsVeterans Affairs Medical Center MemphisMemphis,TNMary N. Felando, MS, RD, CLS, FNLANutrition ConsultantLos Alamitos, CALarry B. Goldstein, MD, FAAN, FAHAProfessor of Medicine (Neurology)Director, Duke Stroke CenterDuke University Medical CenterDurham, NCPaul A. Gurbel, MDDirector, Sinai Hospital, Center for Thrombosis ResearchBaltimore, MDPaul N. Hopkins, MD, MSPH*Professor of Internal MedicineUniversity of UtahCardiovascular GeneticsSalt Lake City, UTMatthew K. Ito, PharmD, FCCP, CLS, FNLAPresident-Elect, National Lipid AssociationProfessor of Pharmacy PracticeOregon State UniversityOregon Health & Science UniversityCollege of PharmacyPortland Campus at Oregon Health & Science UniversityPortland, ORIshwarlal Jialal, MD, PhD, FNLA*Robert E. Stowell Endowed ChairExperimental PathologyDirector of the Laboratory forAtherosclerosis and Metabolic ResearchProfessor of Internal Medicine(Endocrinology, Clinical Nutrition and Vascular Medicine)UC Davis Medical CenterSacramento, CASekar Kathiresan, MDAssistant Professor of MedicineDirector,Preventive CardiologyHarvard Medical SchoolAssociate MemberMassachusetts General HospitalBroad InstituteBoston, MAMarlys L. Koschinsky, PhDProfessor, Department of Chemistry and BiochemistryDean, Faculty of ScienceUniversity of WindsorWindsor, Ontario, CanadaDonald M. Lloyd-Jones, MD, ScMNorthwestern UniversityEileen M. Foell Professor of Preventive Medicine andMedicineSenior Associate Dean,Clinical and Translational ResearchChair, Department of Preventive MedicineDirector, Northwestern University Clinical and TranslationalSciences (NUCATS) InstituteProfessor of Preventive Medicine and MedicineChicago, ILRachel H. Mackey, PhD, MPH, FAHAAssistant Professor of EpidemiologyUniversity of Pittsburgh Graduate School of Public HealthPittsburgh, PAKevin C. Maki, PhD, FNLA, CLSChief Science OfficerBiofortis Clinical ResearchAddison, ILCatherine J. McNeal, MD, PhD, FNLA*Associate Professor of Pediatrics and Internal MedicineTexas A&M Health Science CenterScott & White HealthcareTemple,TXPatrick M. Moriarty, MD, FNLAProfessor of MedicineDirector,Atherosclerosis/LDL-Apheresis Ctr.Division of Clinical PharmacologyUniversity of Kansas Medical CenterKansas City, KSNaima Moustaid-Moussa, PhDProfessor/Nutritional SciencesTexas Tech UniversityCollege of Human SciencesLubbock,TXEileen S. Myers, MPH, RD, LDNSr. DirectorHealthcare Alliance & Health ManagementThe Little ClinicNashville,TNJoseph F. Polak, MD, MPHProfessor of RadiologyTufts University School of MedicineDirector, Ultrasound Reading CenterTufts Medical CenterJamaica Plain, MAOswald Quehenberger, PhDProfessor, School of MedicineUniversity of California, San DiegoLa Jolla, CASanjay Rajagopalan, MD, FACC, FAHAJohn W.Wolfe Professor of Cardiovascular MedicineThe Ohio State University School of MedicineColumbus, OHPaul M. Ridker, MD, MPHEugene Braunwald Professor of MedicineHarvard Medical SchoolDirector, Center for Cardiovascular Disease PreventionBrigham and Women’s HospitalBoston, MAVirend K. Somers, MD, PhDProfessor of MedicineConsultant in Cardiovascular DiseasesDirector, Sleep and Cardiovascular Clinical Research UnitsMayo Clinic and Mayo FoundationRochester, MNNeil J. Stone, MD, MACP, FAHA, FACC, FNLA*Bonow Professor of MedicineFeinberg School of MedicineNorthwestern UniversitySuzanne and Milton Davidson DistinguishedPhysician and Medical Director,Vascular Center of theBluhm Cardiovascular Institute of Northwestern MemorialHospitalChicago, ILAllen J. Taylor MD, FACC, FAHAChief, Cardiology DivisionGeorgetown University HospitalMedstar Heart InstituteWashington, DCPeter P. Toth, MD, PhD, FNLA*President, National Lipid AssociationDirector of Preventative CardiologyCGH Medical CenterSterling, ILProfessor of Clinical Family and Community MedicineUniversity of Illinois College of MedicinePeoria, ILProfessor of Clinical MedicineMichigan State University College of Osteopathic MedicineEast Lansing, MIKasey C. Vickers, PhDNational Heart, Lung and Blood InstituteNational Institutes of HealthBethesda, MDGeorgirene D. Vladutiu, PhDProfessor of Pediatrics, Neurology, and Pathology andAnatomical SciencesThe University at BuffaloBuffalo, NYRobert A. Wild, MD, PhD, MPH, FNLA*Professor and ChiefGynecology, Clinical Epidemiology, MedicineUniversity of Oklahoma Health Sciences CenterOklahoma City, OKDonnie P. Wilson, MD, FNLA*Director,Pediatric Lipid ClinicCook Children’s Medical CenterFort Worth,TXNorman C.W. Wong, MD, FRCP(C)Professor of MedicineBiochemistry and Molecular BiologyFaculty of MedicineUniversity of CalgaryCalgary,Alberta, CanadaPeter P. Toth, MD, PhD, FNLA*President, National Lipid AssociationDirector of Preventative CardiologyCGH Medical CenterSterling, ILProfessor of Clinical Family andCommunity MedicineUniversity of Illinois College of MedicinePeoria, ILProfessor of Clinical MedicineMichigan State University College ofOsteopathic MedicineEast Lansing, MIJ. Antonio G. Lopez, MD, FACC, FAHA,FNLA*President, Pacific Lipid AssociationDirector,Preventive Cardiology, CardiovascularRehabilitation,Lipid Clinic and LDL Apheresis ProgramSaint Alphonsus Regional Medical CenterBoise, IDMatthew K. Ito, PharmD, FCCP, CLS,FNLAPresident-Elect, National Lipid AssociationProfessor of Pharmacy PracticeOregon State UniversityOregon Health and Science UniversityCollege of PharmacyPortland Campus at Oregon Health andScience UniversityPortland, ORB. Alan Bottenberg, DO, FACOI, FNLA*President-Elect, Pacific Lipid AssociationPhysicianCarson Tahoe HospitalNorthern Nevada LipidologyInternal Medicine AssociatesCarson City, NVThe NLA invites speakers and guests to provide scientific and medical opinion, which does not necessarily reflect the policy of the NLA. *Denotes Diplomate of the American Board of Clinical Lipidology (ABCL)PROGRAM CHAIRS& FACULTYP R O G R A M C H A I R SP R O G R A M F A C U L T Y
  8. 8. Call For AbstractsThe 2013 NLA Annual Scientific SessionsCommittee invites the submission of abstracts tobe presented at the 2013 NLA Annual ScientificSessions in Las Vegas, from May 30−June 2,2013. Submitted abstracts will be consideredfor poster presentation and oral presentation atthe meeting.All accepted abstracts will bepublished in the May/June 2013 edition of theJournal of Clinical Lipidology.All abstracts must be submitted online via theNLA abstract submission website using theonline submission form. Please be sure to readall instructions, information and policies closely.Abstract Submission DeadlineFriday, March 1, 20135:00 PM PDTAbstract Acceptance NotificationMonday,April 1, 2013Presenting Author Registration DeadlineFriday, May 10, 2013Presentation MethodsIn addition to posters being displayed at themeeting during the designated hours, selectedabstract submissions will be identified for a liveoral presentation session.The NLA Abstract Review Committee will selectthree abstracts to be presented during adesignated session on the meeting program.Authors will have 8−10 minutes to present theirresearch, with three minutes to follow forquestions and answers.When completing the online abstract submissionform, you will be asked to indicate your interestin having your research considered for the oralpresentation session.Travel Grants and AwardsNLA Young Investigator AwardsSponsored by LipoScience, Inc.Lead presenters with accepted abstracts whoare Young Investigators (in training students,residents and fellows or members in practice for< 5 years) will have the chance to compete forthe NLAs enhanced Young Investigator Awardoffering a $1,000 cash prize and certificate tofirst place and a $500 cash prize to second andthird place.The Award winners will receiverecognition at a special ceremony on Saturday,June 1, 2013. In addition, the first place winnerwill be selected to present their abstract duringthe live Oral Presentation session and have theirposter printed in the Lipid Spin following themeeting.To encourage professional development and specialization in Clinical Lipidology, the NLA invites Fellows and Allied Health Trainees to participate in theNLA Lipid Academy™ (May 29–30) at no charge and the Scientific Sessions (May 31–June 2) at a significantly reduced registration rate. In addition,the NLA will offer $500 travel grants (maximum of 15) to help cover the cost of trainee travel and accommodations. Program Directors, Fellows andTrainees may submit their registration and travel grant requests to sgoode@lipid.org or call the NLA office at 904-998-0854.SPECIAL EVENTS“Dancing in the Desert”Date: Saturday, June 1, 2013Time: 7:00–10:00 PMCost: $175.00Join us for an evening poolside to go “Dancing in theDesert” with the Foundation of the NLA.The RedRock’s luxurious pools provide the perfect setting toenjoy a warm summer night in Las Vegas. Let yourhair down and dress in your best casual clothingwhile you eat, drink and have a little fun in the photobooth that will be set up during the event. Separateregistration is required for this event.H O N O R S & A W A R D S C E R E M O N YSaturday, June 1–6:00–7:00 PMThe National Lipid Association, in cooperation with thecertification bodies of the American Board of Clinical Lipidology(ABCL) and the Accreditation Council for Clinical Lipidology(ACCL) will host its annual Honors and Awards Ceremony.The ABCL and ACCL will recognize the achievements of thosewho successfully passed the ABCL or Clinical Lipid Specialist(CLS) exams.The NLA will present the Distinguished AchievementAward, the Honorary Lifetime Member Award, and the President’sService Award, as well as induct the 2013 class of Fellows ofthe NLA.F E L L O W S - I N - T R A I N I N G T R A V E L G R A N T S A V A I L A B L EP O S T E R S E S S I O N S
  9. 9. Red Rock Resort11011 West Charleston BoulevardLas Vegas, Nevada 89135866.767.7773For reservations, call 1.866.767.7773 and ask for the National Lipid Associationroom block.A special room rate starting at $145 per night plus tax has beenarranged.This rate is available until May 6, or until the room block is filled. Makeyour reservations early as the room block is expected to sell out.About the VenueThe Red Rock Resort represents the pinnacle in Las Vegas casino resort hotels.Red Rock offers guests an idyllic getaway at the top of one of America’s mostvibrant cities. Ideally situated at the entrance to Red Rock Canyon and minutesfrom the world-renowned Las Vegas Strip, you couldn’t ask for a more excitingplace to play, both indoors and out.Amenities include The Spa at Red Rock,award-winning dining, casino gaming, and live entertainment.CONFERENCE VENUEViva Las Vegas!Las Vegas continues to build upon its reputation as a vibrant showcase for theextraordinary.This is the city that attracts more than 38.9 million visitors a year byoffering the grandest hotels, the biggest stars in entertainment, thehighest caliber of award-winning chefs and master sommeliers, and,of course, the brightest lights.Entertainment CapitalThere are many reasons why Las Vegas commands the titleas “The Entertainment Capital of the World." Some of theworlds most exciting and versatile entertainers performhere including Celine Dion, Elton John, Jerry Seinfeld, Jay Leno, Garth Brooks, and so manymore.Also, hot-selling tickets include Broadway hits such as Jersey Boys and Tony & TinasWedding. Popular touring Broadway shows stop at the Smith Center for the Performing Arts in downtownLas Vegas. Other entertainment options include several resident Cirque du Soleil productions, comedy clubs,classic Las Vegas showgirl revues, and more.World-Class CuisineWhile planning an evening of entertainment, look to the growing roster of gourmetrestaurants and unparalleled wine and food adventures in Las Vegas.A host offine dining and lifestyle magazines including−Bon Appetit,Wine Spectator,Gourmet, Robb Report and Esquire−have honored the city for its fantastic fareand hailed individual restaurants for their exquisite cuisine.Fields of GreenWhether you are dancing under the lights of the Fremont Street Experience indowntown Las Vegas or strolling the shops at Monte Lago Village at Lake Las Vegas,you are never far from a golf course.The 50-plus golf courses have put Vegas on themap for golf connoisseurs. Each course is within a one-hour radius of the city,offering challenging play and beautiful desertscapes, flowing waterfalls, rollinggreens and mountain views.History and NatureHistory buffs will enjoy a tour of the Hoover Dam, less than an hours drive east ofLas Vegas, or a visit to Bonnie Springs Old Nevada, where your family can enjoy ataste of the Wild West outside the western outskirts of the city. Or head south totrek underground in the Eldorado Canyon Mines, the oldest gold mine in SouthernNevada, located just adjacent to the ghost town of Nelson.For adventurers, the breathtaking scenery and mildweather in southern Nevada will be compellingenticement to go horseback riding or mountain bikingin Red Rock Canyon, river rafting in nearby BoulderCitys Black Canyon, and hiking and rock climbing inthe Desert National Wildlife Refuge.
  10. 10. PRE-CONFERENCECOURSE ACCREDITATIONLipid Academy™ Course– AccreditationCME credit provided by the National Lipid AssociationPhysiciansThe National Lipid Association is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.The National Lipid Associationdesignates this live activity for a maximum of 10.5 AMA PRACategory 1 Credits™. Physicians should claim only creditcommensurate with the extent of their participation in the activity.Physician AssistantsNCCPA accepts AMA PRA Category I Credit™ from organizationsaccredited by ACCME.CE Credit provided by Postgraduate Institutefor MedicinePharmacistsPostgraduate Institute for Medicine is accredited by theAccreditation Council for Pharmacy Education as a providerof continuing pharmacy education.Session 1–Universal Activity Number–0809-9999-13-001-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 6.75 contact hour(s) (.675 CEUs) of theAccreditation Council for Pharmacy Education.Session 2–Universal Activity Number–0809-9999-13-002-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 3.75 contact hour(s) (.375 CEUs) of theAccreditation Council for Pharmacy Education.NursingThis educational activity for 10.5 contact hours is provided byPostgraduate Institute for Medicine.Postgraduate Institute for Medicine is accredited as a provider ofcontinuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.DietitiansThe following program has been submitted for approval to theCommission on Dietetic Registration (CDR) for 10.5 credits.Criteria for SuccessStatements of credit will be awarded based on the participant’sattendance and submission of the activity evaluation form.Astatement of credit will be available upon completion of an onlineevaluation/claimed credit form at www.lipid.org/cme.For Pharmacists: Upon receipt of the completed activity evaluationform, transcript information will be available atwww.mycpemonitor.net within 4 weeks.Disclosure StatementIt is the policy of NLA to ensure independence, balance, objectivity,scientific rigor, and integrity in all of its continuing educationactivities.The faculty must disclose to the participants any significantrelationships with commercial interests whose products or devicesmay be mentioned in the activity or with the commercial supporter ofthis continuing education activity. Identified conflict of interest isresolved by NLA prior to accreditation of the activity. NLA plannersand reviewers have no relevant financial relationships to disclose.Commercial SupportFull notification of commercial support will be provided in the activitysyllabus.Masters in Lipidology™ Course–AccreditationCME credit provided by the National Lipid AssociationPhysiciansThe National Lipid Association is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.The National Lipid Associationdesignates this live activity for a maximum of 16 AMA PRA Category1 Credits™. Physicians should claim only credit commensurate withthe extent of their participation in the activity.Physician AssistantsNCCPA accepts AMA PRA Category I Credit™ from organizationsaccredited by ACCME.CE Credit provided by Postgraduate Institutefor MedicinePharmacistsPostgraduate Institute for Medicine is accredited by theAccreditation Council for Pharmacy Education as a provider ofcontinuing pharmacy education.Session 1–Universal Activity Number–0809-9999-13-003-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 8.50 contact hour(s) (.850 CEUs) of theAccreditation Council for Pharmacy Education.Session 2–Universal Activity Number–0809-9999-13-004-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 7.50 contact hour(s) (.750 CEUs) of theAccreditation Council for Pharmacy Education.NursingThis educational activity for 15.9 contact hours is provided byPostgraduate Institute for Medicine.Postgraduate Institute for Medicine is accredited as a provider ofcontinuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.DietitiansThe following program has been submitted for approval to theCommission on Dietetic Registration (CDR) for 16 credits.Criteria for SuccessStatements of credit will be awarded based on the participant’sattendance and submission of the activity evaluation form.Astatement of credit will be available upon completion of an onlineevaluation/claimed credit form at www.lipid.org/cme.For Pharmacists: Upon receipt of the completed activity evaluationform, transcript information will be available atwww.mycpemonitor.net within 4 weeks.Disclosure StatementIt is the policy of NLA to ensure independence, balance, objectivity,scientific rigor, and integrity in all of its continuing educationactivities.The faculty must disclose to the participants any significantrelationships with commercial interests whose products or devicesmay be mentioned in the activity or with the commercial supporter ofthis continuing education activity. Identified conflict of interest isresolved by NLA prior to accreditation of the activity. NLA plannersand reviewers have no relevant financial relationships to disclose.Commercial SupportFull notification of commercial support will be provided in the activitysyllabus.The Translation of HDL Science MasterClass–AccreditationCME credit provided by the National Lipid AssociationPhysiciansThe National Lipid Association is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.The National Lipid Associationdesignates this live activity for a maximum of 10.25 AMA PRACategory 1 Credits™. Physicians should claim only creditcommensurate with the extent of their participation in the activity.Physician AssistantsNCCPA accepts AMA PRA Category I Credit™ from organizationsaccredited by ACCME.CE Credit provided by Postgraduate Institutefor MedicinePharmacistsPostgraduate Institute for Medicine is accredited by theAccreditation Council for Pharmacy Education as a providerof continuing pharmacy education.Day 1–Morning Session–Universal Activity Number–0809-9999-13-005-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.75 contact hour(s) (.175 CEUs) of theAccreditation Council for Pharmacy Education.Day 1–Afternoon Session–Universal Activity Number–0809-9999-13-006-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 4.50 contact hour(s) (.450 CEUs) of theAccreditation Council for Pharmacy Education.Day 2–Universal Activity Number–0809-9999-13-007-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 3.75 contact hour(s) (.375 CEUs) of theAccreditation Council for Pharmacy Education.NursingThis educational activity for 9.9 contact hours is provided byPostgraduate Institute for Medicine.Postgraduate Institute for Medicine is accredited as a provider ofcontinuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.Day 1–Morning–1.7 contact hours;Day 2–Afternoon–4.5 contact hours;Day 2–3.7 contact hours.DietitiansThe following program has been submitted for approval to theCommission on Dietetic Registration (CDR) for 10.25 credits.Criteria for SuccessStatements of credit will be awarded based on the participant’sattendance and submission of the activity evaluation form.Astatement of credit will be available upon completion of an onlineevaluation/claimed credit form at www.lipid.org/cme.For Pharmacists: Upon receipt of the completed activity evaluationform, transcript information will be available atwww.mycpemonitor.net within 4 weeks.Disclosure StatementIt is the policy of NLA to ensure independence, balance, objectivity,scientific rigor, and integrity in all of its continuing educationactivities.The faculty must disclose to the participants any significantrelationships with commercial interests whose products or devicesmay be mentioned in the activity or with the commercial supporter ofthis continuing education activity. Identified conflict of interest isresolved by NLA prior to accreditation of the activity. NLA plannersand reviewers have no relevant financial relationships to disclose.Commercial SupportFull notification of commercial support will be provided in the activitysyllabus.Jointly hosted by theSoutheast and Northeastregional chaptersSeptember 20–22, 2013Hyatt Regency BaltimoreBaltimore, MDProgram Highlights include:• Evidence-based presentation direct from world-renowned thoughtleaders• Challenging case-based plenary sessions• More than 20 CME/CE credits available for physicians, nurses,pharmacists, and registered dietitians• Professional development courses to enhance your skillsStay tuned to www.lipid.org/fallclu for updates.Save the DateDon’t Miss the National Lipid Association’s Clinical Lipid Update
  11. 11. Registration:RegistrationandpaymentmustbereceivednolaterthanMay3,2013.Afterthisdateasyllabusandnamebadgecannotbeguaranteed.Cancellation:Telephonecancellationswillnotbeaccepted.AwrittennoticeofcancellationmustbereceivednolaterthanMay3,2013.Thisincludessocialeventsandguestfees.Therewillbea$25feeforallcancellations.Guestname(s),ifattendingmeeting:Specialneeds:ADACompliance:AttendeeswhoneedadditionalreasonableaccommodationsorwhohavespecialneedsshouldcontacttheNLAat904.998.0854.*Master’sCourse:TopurchasetheNLA-SAPspleasegoto:www.lipid.org/education/nlasap.†TraineeRate:Availableforthoseindividualsactivelyenrolledinagraduateorpostgraduatetrainingprogramforthetreatmentorinvestigationoflipiddisordersandinpursuitoffullcredentialingintheirspecializedareaofmedicalstudy.Aletterfromtheprogramdirectorortheschoolregistrarmustaccompanytheapplication.3EasyWaysToRegisterMailNationalLipidAssociation6816SouthpointParkway,Suite1000Jacksonville,FL32216FaxNLAat904.998.0855FaxwithcreditcardnumberandsignatureOnlinewww.lipid.org/sessionsREGISTRATIONFirstNameMiddleInitialLastNameMailingAddressCityStateorProvinceZipCountryPhoneEmergencyContact/PhoneEmailCheckallthatapply:ⅪMD/DO/PhDⅪRNⅪNPⅪPAⅪRPHⅪPharmDⅪRDOther_____Scanthiscodewithyoursmartphoneortablettoregisternow.2013NLAAnnualScientificSessionsHostedbythePacificregionalchapterMay30–June2•RedRockHotel•LasVegasCirclefeebasedonattendeetypeⅪScientificSessionsMay30–June2,2013IncludescoursesyllabusandoneadmissionbadgetoExhibitHallforallfoodfunctions.AncillaryCoursesⅪMastersinLipidologyTMCourse*May29-30,2013$695$695$1,200$395ⅪNLALipidAcademy™May29-30,2013$495$495$900$0ⅪTranslationofHDLScienceMasterClassMay29-30,2013$225$225$495N/ARegistrationFeeTotal$_____$_____$_____$_____GuestFees&EventsⅪExhibitHallPass–Guest(s)$150$150X____$____ⅪDancingintheDesert$175$175X____$____CombinedTotalSections2,3&4$_____PaymentMethodⅪVISAⅪMCⅪAMEXⅪCheckMakecheckspayabletotheNLANLAMemberNLAMemberNon-MemberTraineeDiscountRateDiscountRateRegistrantRateRate†before3/29/13after3/29/13$525$595$1,000$75CreditCard#Exp.DateSignatureNameonCard12345PRE-CONFERENCECOURSE ACCREDITATIONAnnual Scientific Sessions CME/CEAccreditationCME credit provided by the National Lipid AssociationPhysiciansThe National Lipid Association is accredited by the AccreditationCouncil for Continuing Medical Education to provide continuingmedical education for physicians.The National Lipid Associationdesignates this live activity for a maximum of 14.75 AMA PRACategory 1 Credit(s)™. Physicians should claim only creditcommensurate with the extent of their participation in the activity.Physician AssistantsNCCPA accepts AMA PRA Category I Credit™ from organizationsaccredited by ACCME.American Academy of Family PhysiciansApplication for CME credit has been filed with the American Academyof Family Physicians. Determination of credit is pending.DietitiansThe National Lipid Association is a Continuing Professional Education(CPE) Accredited Provider with the Commission on DieteticRegistration (CDR). Registered dietitians (RDs) and dietetictechnicians, registered (DTRs) will receive 1.00 (Keynote); 1.5(Session I); 1.25 (Session II); 1.5 (Session III); 1.5 (Session IV);1.25 (Session V); 1.75 (Session VI); 1.25 (Session VII); .75 (SessionVIII); 2.0 (Session IX) continuing professional education units(CPEUs) for completion of this program/material.CE credit provided by Postgraduate Institutefor MedicinePharmacistsPostgraduate Institute for Medicine is accredited by theAccreditation Council for Pharmacy Education as a provider ofcontinuing pharmacy education.Session Keynote Lecture–Universal Activity Number0809-9999-13-243-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.0 contact hour(s) (.1 CEUs) of theAccreditation Council for Pharmacy Education.Session I–Universal Activity Number0809-9999-13-244-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.5 contact hour(s) (.15 CEUs) of theAccreditation Council for Pharmacy Education.Special Session New Lipid Guidelines Perspectives–Universal Activity Number 0809-9999-13-253-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for .50 contact hour(s) (.05 CEUs) of theAccreditation Council for Pharmacy Education.Special Session Vulnerable Blood–Universal Activity Number0809-9999-13-254-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for .50 contact hour(s) (.05 CEUs) of theAccreditation Council for Pharmacy Education.Session II–Universal Activity Number0809-9999-13-245-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.25 contact hour(s) (.125 CEUs) of theAccreditation Council for Pharmacy Education.Session III–Universal Activity Number0809-9999-13-246-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.5 contact hour(s) (.15 CEUs) of theAccreditation Council for Pharmacy Education.Session IV–Universal Activity Number0809-9999-13-247-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.5 contact hour(s) (.15 CEUs) of theAccreditation Council for Pharmacy Education.Session V–Universal Activity Number0809-9999-13-248-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.25 contact hour(s) (.125 CEUs) of theAccreditation Council for Pharmacy Education.Session VI–Universal Activity Number0809-9999-13-249-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.75 contact hour(s) (.175 CEUs) of theAccreditation Council for Pharmacy Education.Session VII–Universal Activity Number0809-9999-13-250-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for 1.25 contact hour(s) (.125 CEUs) of theAccreditation Council for Pharmacy Education.Session VIII–Universal Activity Number0809-9999-13-251-L01-P (Knowledge)Postgraduate Institute for Medicine designates this continuingeducation activity for .75 contact hour(s) (.075 CEUs) of theAccreditation Council for Pharmacy Education.Session IX–Universal Activity Number0809-9999-13-252-L01-P (Application)Postgraduate Institute for Medicine designates this continuingeducation activity for 2.0 contact hour(s) (.2 CEUs) of theAccreditation Council for Pharmacy Education.NursingThis educational activity for 14.5 contact hours is provided byPostgraduate Institute for Medicine.Postgraduate Institute for Medicine is accredited as a provider ofcontinuing nursing education by the American Nurses CredentialingCenter’s Commission on Accreditation.Keynote Lecture–1.0 contact hoursSession I–1.5 contact hoursSpecial Session New Lipid Guidelines Perspectives–.50 contact hoursSpecial Session Vulnerable Blood–.50 contact hoursSession II–1.2 contact hoursSession III–1.5 contact hoursSession IV–1.5 contact hoursSession V–1.2 contact hoursSession VI–1.7 contact hoursSession VII–1.2 contact hoursSession VIII–.70 contact hoursSession IX–2.0 contact hours.Criteria for SuccessStatements of credit will be awarded based on the participant’sattendance and submission of the activity evaluation form.Astatement of credit will be available upon completion of an onlineevaluation/claimed credit form at www.lipid.org/cme.For Pharmacists: Upon receipt of the completed activity evaluationform, transcript information will be available atwww.mycpemonitor.net within 4 weeks.Disclosure StatementIt is the policy of NLA to ensure independence, balance, objectivity,scientific rigor, and integrity in all of its continuing educationactivities.The faculty must disclose to the participants any significantrelationships with commercial interests whose products or devicesmay be mentioned in the activity or with the commercial supporter ofthis continuing education activity. Identified conflict of interest isresolved by NLA prior to accreditation of the activity. NLA plannersand reviewers have no relevant financial relationships to disclose.Commercial SupportFull notification of commercial support will be provided in the activitysyllabus.Register online at: www.lipid.org/sessionsTrim Here
  12. 12. 6816SouthpointParkway,Suite1000Jacksonville,FL32216ScanthiscodewithyoursmartphoneortabletformoreinformationScan this code with your smartphone ortablet for more informationREGISTERATWWW.LIPID.ORG/SESSIONS2013 NLA AnnualScientific Sessions2013NLAAnnualScientificSessionsRedRockResort11011WestCharlestonBoulevardLasVegas,Nevada89135866.767.7773REGISTERATWWW.LIPID.ORG/SESSIONS The NLA meetings are aMUST if you want to beup-to-date regardinglipid managementand CVD prevention.–Scientific Sessions Attendee”“OverviewEach day of the conference, thought leaders will present casesand discuss the latest research, guidelines, controversies andclinical strategies on lipid management:NLA Town Hall: Role of PCSK9 Inhibition onIntensive Lipid LoweringKeynote Lecture: Sterol-Regulatory-Element-Binding-ProteinsFeatured SessionsⅢ Focus on Metabolic SyndromeⅢ New Lipid Guidelines PerspectivesⅢ Special Session on Vulnerable BloodⅢ Fish Oil SymposiumⅢ HDL Translational ScienceⅢ Statin Safety Update: A Focus on theMechanismsⅢ Pediatric Session: What Age to InitiatePharmacotherapy?Ⅲ General Session: Vascular Biology andAdvanced Lipoprotein MetabolismⅢ Assessing CVD RiskⅢ Debate – CIMT as a Risk MarkerⅢ Clinical ApplicationsPre-Conference Training CoursesMay 29–May 30, 2013Scientific SessionsMay 30–June 2, 2013R E G I S T E R A T W W W . L I P I D . O R G / S E S S I O N SEarlyBirdDiscountof$525isAvailableuntilMarch29,2013

×